The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis

Min Deng¹, Xin Zhou¹, Sheng Gao², Shi-Gui Yang¹, Bing Wang¹, Hua-Zhong Chen³ and Bing Ruan¹*

Abstract
Chronic hepatitis B virus (HBV) infection poses a serious public health problem in many parts of the world. Presently, even with proper joint immunoprophylaxis, approximately 10-15% of newborns from HBV carrier mothers suffer from HBV infection through intrauterine transmission. One of the risk factors is the level of maternal viraemia. Telbivudine is a synthetic thymidine nucleoside analogue with activity against HBV. A few studies have evaluated the efficacy of telbivudine in preventing intrauterine HBV infection during late pregnancy. So we conducted this meta-analysis to arrive at an evidence-based conclusion. We searched Medline/PubMed, EMBASE, Cochrane Library, Web of Knowledge and China Biological Medicine Database from January 1990 to December 2011. Relative risks (RR) of the seropositivity rates for hepatitis B surface antigen (HBsAg) and HBV DNA in newborns and infants were studied. Mean differences (MD) in maternal HBV DNA levels were reviewed. Finally two randomised controlled trials (RCTs) and four non-randomised controlled trials (NRCTs) were left for analysis which included 576 mothers in total, of whom 306 received telbivudine treatment and 270 did not receive any drug. All newborns received hepatitis B vaccine (HBVac) and hepatitis B immunoglobulin (HBIG) after birth. The seropositivity rate for HBsAg or HBV DNA was significantly lower in the telbivudine group, both at birth and at 6–12 months follow up. Meanwhile, maternal HBV DNA levels prior to delivery were significantly lower in the telbivudine group. In addition, the frequency of serum creatine kinase (CK) elevation was similar in the two groups. Our meta-analysis provides preliminary evidence that telbivudine application in late pregnancy is effective in the interruption of intrauterine HBV infection, with no significant adverse effects or complications. More high quality, well-designed, double-blinded, randomised controlled and large size clinical trials are needed for further investigation and more convincing results in the future.

Keywords: Hepatitis B virus, Telbivudine, Intrauterine transmission, Pregnancy

Background
Chronic hepatitis B virus (HBV) infection poses a serious public health problem in many parts of the world, especially in developing countries [1]. In the Asia-Pacific region, vertical transmission of HBV is a key factor in its endemicity. The risk of chronic hepatitis B (CHB) virus infection is inversely proportional to the age at which the infection was acquired [2], and at least 50% of cases acquired the infection during either the perinatal period or in early childhood [3], including through vertical transmission.

Presently, the World Health Organization, the World Gastroenterology Organisation and the Ministry of Health of China recommend joint immunoprophylaxis with the hepatitis B vaccine (HBVac) and hepatitis B immunoglobulin (HBIG) to prevent HBV mother-to-child transmission (MTCT). However, even with proper joint immunoprophylaxis, approximately 10-15% of newborns from HBV carrier mothers suffer from HBV infection through intrauterine transmission [4,5]. Risk factors for HBV immunoprophylaxis failure include maternal hepatitis B e antigen (HBeAg) positivity and increased hepatitis B surface antigen (HBsAg) titre and HBV DNA
levels [6]. High maternal serum HBV DNA loads have been reported to increase the possibility of intrauterine HBV infection [7]. Hence, antiviral therapy plus immunoprophylaxis administered to HBV carrier mothers during pregnancy has been suggested to effectively prevent MTCT by reducing maternal HBV DNA levels and developing passive immunisation in the newborns. The oral nucleoside analogue lamivudine is believed to prevent the HBV intrauterine transmission during the last months of pregnancy [8-10]. Many studies have also shown reliable prevention effects of this drug [8,11,12].

Telbivudine, classified as Food and Drug Administration (FDA) pregnancy risk category B [2,3], is a synthetic thymidine nucleoside analogue with activity against HBV. It was reported that telbivudine treatment produced rapid reduction in serum HBV DNA levels in a 4-week dose-escalation trial and a 1-year trial conducted with Asian and Western CHB patients [13]. Besides, global and Chinese clinical trials have indicated that telbivudine provides greater antiviral and clinical efficacy than lamivudine in patients with HBeAg-positive and HBeAg-negative CHB [13,14].

A few studies have evaluated the efficacy of telbivudine in preventing intrauterine HBV infection during late pregnancy. We performed this meta-analysis to arrive at an evidence-based conclusion. We also investigated the safety of telbivudine during pregnancy.

Methods

Search strategy

Medline/PubMed, EMBASE, Cochrane Library, Web of Knowledge and China Biological Medicine Database were searched for relevant randomised controlled trials (RCTs) aimed at preventing MTCT of HBV by comparing telbivudine with placebo or no treatment (control). Query results included articles published between January 1990 and December 2011 in English or Chinese peer-reviewed publications (including abstracts). Because published studies were limited, we expanded the search to include non-randomised controlled trials (NRCTs). We also hand-searched bibliographies of reviews, original studies and relevant conference articles, and contacted some investigators directly. The search was designed using the key words “telbivudine or Tyzeka or Sebivo”, “HBV or hepatitis B virus” and “intrauterine or maternity or mother or pregnancy or pregnant”.

Inclusion and exclusion criteria

Inclusion criteria included the following: (1) maternal blood was positive for HBsAg and HBV DNA; and (2) the diagnoses of intrauterine HBV infection and MTCT were clear; and (3) mothers were HBV carriers or patients with compensated hepatitis [15]. Studies were excluded if they were reviews, meta-analysis or case reports (with no control group). Because HBIG or other antiviral drugs may reduce serum HBV DNA levels, we also excluded studies in which these were used before labour [16]. All newborns (in both the treatment and control groups) received HBIG and HBVac after birth.

Outcome measures

The primary outcomes were the rates of newborn HBV infection at birth and 6–12 months follow up. Secondary outcomes included maternal blood HBV DNA levels before treatment and prior to delivery, adverse events on the mother (such as elevations in creatine kinase (CK) and aminotransferase (ALT), postpartum haemorrhaging, complications in pregnancy and during delivery), and adverse effects on newborn parameters (such as weight, height and 1-minute Apgar score).

Study quality

Two investigators (Min Deng and Xin Zhou) independently assessed study quality. All RCTs were graded using the Jadad criteria [17]. These criteria include the three methodological features of randomisation, blinding and accountability. NRCTs had to meet the cases matched by the patient’s characteristics. All studies had defined inclusion and exclusion criteria for patients. Disagreements were resolved by consensus when necessary.

Data extraction

Extracted data included patient characteristics, design and methods of the study, inclusion and exclusion criteria, treatment duration and dose, primary and secondary outcomes, complications, and adverse events.

Statistical analysis

Data analysis was carried out with the use of Review Manager Software 5.0 (Cochrane Collaboration). The meta-analysis was performed using the Mantel-Haenszel fixed-effects or random-effects models, depending on the absence or presence of significant heterogeneity [18]. Statistical heterogeneity was assessed by the chi-square (Ch2) test and I-squared (I2) test and was considered to exist when I2 > 50%. We used the relative risk (RR) of the main dichotomous outcomes as the measure of efficacy, which are shown in a forest plot. The 95% confidence interval (CI) for the pooled RR was also provided. Continuous outcomes were presented as a mean difference (MD) because HBV DNA levels of the studies were reported in the same scale (log10 copies/ml measured by the Polymerase Chain Reaction). Subgroup analysis was conducted to compare the effects in different study types (RCT or NRCT). A funnel plot estimating the precision of trials was examined to evaluate the potential for selection bias. The overall effect of intervention achieved statistical significance if P < 0.05. Because we used only
previously published data, approval from the ethics committee was not required.

Results
Characteristics of the studies
We identified 1,712 citations through our searches, from which six studies involving 576 mothers (306 of whom were treated with telbivudine) were selected [5,19-23]. A map of the literature search and selection process is shown in Figure 1. Of the studies included, five were published in Chinese [19-23] and one was published in English as original articles [5]. Two studies were RCTs [19,22], but they did not describe the method of randomisation in detail and received Jadad scores of 2. Two studies were not included in our meta-analysis because of the use of telbivudine in combination with HBIG before labour [24,25]. In the trial by Han et al. [5], one mother in the telbivudine group had twins, and 10 mothers and their infants (4 in the telbivudine group and 6 in the control group) dropped out at 7 months postpartum. The characteristics of the six included studies are shown in Table 1.

Newborn and infant HBsAg seropositivity
Five studies (1 RCT and 4 NRCTs) demonstrated newborn HBsAg seropositivity at birth [5,19-21,23]. The newborn HBsAg positive rates were 8.7% (24/277) in the telbivudine group and 27.1% (65/240) in the control group. Based on the Chi² and I² analyses [Chi² = 0.28, df = 4 (P = 0.99); I² = 0%], a fixed-effects approach was used to summary estimate the relative risk of telbivudine versus control. The pooled data demonstrated that newborn HBsAg seropositivity was higher in the control group than in the telbivudine group [RR = 0.31, 95% CI (0.20, 0.49), P < 0.00001]. We further conducted meta-analysis based on study type (RCT or NRCT) to minimise the potential heterogeneity. However, regarding this parameter, only one RCT [19] could be included. Thus, we pooled the data from the four NRCTs [5,20,21,23]. We found that newborn HBsAg seropositivity was lower in the telbivudine group than in the control group [RR = 0.31, 95% CI (0.20, 0.49), P < 0.00001] (Figure 2). The results were consistent.

At age 6–12 months, the infant HBsAg positive rates were 0.7% (2/281) in the telbivudine group and 12.2% (29/238) in the control group (2 RCTs and 3 NRCTs) [5,19,21-23]. Based on the Chi² and I² analyses, significant differences in heterogeneity were not observed between the two groups [Chi² = 1.41, df = 4 (P = 0.84); I² = 0%]. A summary estimate of the relative risk of telbivudine versus control showed a significant difference [RR = 0.11, 95% CI (0.04, 0.31), P < 0.0001]. We also conducted meta-analysis for two RCTs [19,22] and three NRCTs [5,21,23]. The pooled RR of the two RCTs was 0.20 [95% CI (0.04, 1.10)]. Although it did not achieve statistical significance (P = 0.06), there was a
| Study       | Study design | Telbivudine/Control (n) | HBeAg (+) (-) (n) | Baseline ALT (U/L) | HBV DNA level (log copies/ml) | Treatment | Newborn immunization |
|-------------|--------------|-------------------------|-------------------|--------------------|-------------------------------|-----------|----------------------|
|             |              | Telbivudine | Control | Telbivudine | Control | Lower enrollment limit | Telbivudine | Control | HBIG (IU) | HVB ac (mg) |
| Zhang 2009  | RCT          | 31/30       | NA      | NA        | NA      | Mean (SD): 7.38 (0.81)   | Control     | 7       | 600 at 28-32 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
| Zhao 2010   | RCT          | 30/30       | 30/0    | Normal (NA)| Normal (NA) | Mean (SD): 7.460 (0.45)   | Control     | 7       | 600 from 28 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
| Zeng 2010   | NRCT         | 22/26       | 22/0    | Normal (NA)| Normal (NA) | Mean (SD): 7,460 (0.45)   | Control     | 7       | 600 from 28 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
| Zhang 2010  | NRCT         | 60/60       | 60/0    | NA        | NA      | Mean (SD): 7.66 (0.82)    | Control     | 7       | 600 from 28 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
| Yao 2011    | NRCT         | 28/30       | NA      | NA        | Mean (SD): 936 (226.8)   | Mean (SD): 7.50 (0.60) | Control | 7       | 600 from 28 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 30 d | 10 at 0, 1, 6 mo |
| Han 2011    | NRCT         | 135/94      | 135/0   | 94/0     | Mean (SD): 35.67 (43.41) | Mean (SD): 8.10 (0.56) | Control | 7       | 600 from 20-32 wk of gestation to 1 mo after delivery | No treatment | 200 at birth and 15 d | 20 at 0, 1, 6 mo |

RCT: randomized controlled trial; NRCT: non randomized controlled trial; NA: not available; Mean (SD): mean (standard deviation); HBIG: hepatitis B immunoglobulin; IU: International Unit; HBVac: hepatitis B vaccine.
trend towards a decrease in HBsAg positive rate in infants in the telbivudine group. The pooled results of the three NRCTs showed that the RR was 0.08 [95% CI (0.02, 0.32), P = 0.0004] (Figure 3).

We further explored the selection biases, and found no significant asymmetry of the funnel plots (Figure 4). The immunoprophylaxis outcomes for newborns and infants are shown in Table 2.

Newborn and infant HBV DNA seropositivity
Only three NRCTs examined in this meta-analysis reported HBV DNA seropositivity at birth [5,20,21]. The
Figure 4 (See legend on next page.)
newborn HBV DNA positive rates were 2.3% (5/218) in the telbivudine group and 17.2% (31/180) in the control group. Using the Chi² and I² analyses, heterogeneity was assessed and not found to be significant [Chi² = 2.14, df = 2 (P = 0.34); I² = 6%]. The pooled data of the three studies showed a significant difference between the two groups [RR = 0.18, 95% CI (0.08, 0.40), P < 0.0001] (Figure 5).

At age 6–12 months, three trials (1 RCT and 2 RCTs) demonstrated infant HBV DNA seropositivity [5,21,22]. The infant HBV DNA positive rates were 0.9% (2/222) in the telbivudine group and 14.6% (26/178) in the control group. According to Chi² and I² analyses, significant differences in heterogeneity were not observed [Chi² = 0.34, df = 2 (P = 0.84); I² = 0%]. A summary estimate of the relative risk of telbivudine versus control using a fixed-effects approach demonstrated that there was a significant difference in infant HBV DNA seropositivity between two groups [RR = 0.09, 95% CI (0.02, 0.30), P = 0.0001]. As only one RCT [22] could be included in this meta-analysis, we pooled the data from the two NRCTs [5,21]. We found that the results were consistent [RR = 0.07, 95% CI (0.01, 0.36), P = 0.001] (Figure 6).

We further explored the selection biases of the outcomes, and found no significant asymmetry of the funnel plots (Figure 4).

Maternal blood HBV DNA levels
Five studies (1 RCT and 4 NRCTs) described maternal blood HBV DNA levels before telbivudine treatment in detail [5,19-23]. Heterogeneity was assessed and not found to be significant [Chi² = 3.52, df = 4 (P = 0.48); I² = 0%]. A summary estimate of the MD of telbivudine versus control using a fixed-effects approach demonstrated that maternal blood HBV DNA levels were similar before telbivudine treatment [MD = 0.09, 95% CI (−0.04, 0.22), P = 0.16]. As we had to exclude one RCT [19], we conducted a meta-analysis for the four NRCTs [5,20,21,23]. The pooled data also showed no significant difference in maternal blood HBV DNA levels before treatment [MD = 0.12, 95% CI (−0.02, 0.26), P = 0.08] (Figure 7).

Also among the five studies, Chi² and I² analyses identified significant heterogeneity in maternal blood HBV DNA levels between two groups prior to delivery [Tau² = 1.35, Chi² = 97.90, df = 4 (P < 0.00001); I² = 96%]. A summary estimate of the MD of telbivudine versus control using a random-effects approach demonstrated that the maternal blood HBV DNA level was lower in the telbivudine group prior to delivery [MD = −4.06, 95% CI (−5.13, -2.98), P < 0.00001]. We also further performed a meta-analysis among the four NRCTs, and the results were consistent [MD = −4.27, 95% CI (−5.43, -3.11), P < 0.00001] (Figure 8).

In addition, we explored the selection biases, and found no significant asymmetry of the funnel plots (Figure 4).

Safety
Elevation of serum CK in newborns (8 in the telbivudine group and 9 in the control group) was the only adverse event reported by Zhang et al. [19]. Thirteen mothers presented with elevated CK levels in another study by Zhang et al. [21]. The only reported adverse event in Yao’s trial [23] was elevated CK levels in 3 mothers in the telbivudine group and 2 mothers in the control group. In addition, 5 mothers in Zeng’s study [20] and 88 mothers in Han’s study [5] had light elevation in serum ALT levels after drug withdrawal. At 7 month follow up, pneumonia and other adverse events in infants were evaluated and considered not to be drug related in Han’s study.

Five studies (2 RCTs and 3 NRCTs) examined in this meta-analysis reported serum CK levels in mothers [19-23]. According to Chi² and I² analyses [Tau² = 3.74, Chi² = 3.66, df = 1 (P = 0.06); I² = 73%], a random-effects approach was used to summary estimate the relative risk of telbivudine versus control. The pooled data demonstrated that the frequency of serum CK elevation was similar in the two groups [RR = 5.53, 95% CI (0.24, 124.94), P = 0.28] (Figure 9). Because two studies substantially contributed to the overall effect of the meta-analysis, we did not divide the studies into subgroups to investigate heterogeneity.

We further explored the selection bias, and found no significant asymmetry of the funnel plots (Figure 4).

Discussion
Of the estimated 350 million individuals chronically infected with HBV worldwide, it is generally accepted that at least 50% of cases acquired their infections during either the perinatal period or in early childhood, especially in areas of high endemicity. In China, where the prevalence of HBV is high, 85-90% of transmissions can be prevented successfully with proper
### Table 2 The immunoprophylaxis outcomes for newborns and infants

| Study      | Newborns number | HBsAg seropositivity n (%) | HBV DNA seropositivity n (%) |
|------------|-----------------|-----------------------------|-------------------------------|
|            | Telbivudine/    | Control                     | Telbivudine                   | Control                     | Telbivudine                 | Control                     |
|            | n               | At birth 6 mo 7 mo 12 mo    | At birth 6 mo 7 mo 12 mo      | At birth 6 mo 7 mo 12 mo    | At birth 6 mo 7 mo 12 mo    | At birth 6 mo 7 mo 12 mo    |
| Zhang 2009 [21] | 31/30           | 2 (6.5%) NA 0 (0%) NA      | 5 (16.7%) NA 4 (13.3%) NA    | NA NA NA NA NA NA NA NA NA|
| Zhao 2010 [22] | 30/30           | NA NA NA 1 (3.3%) NA       | NA NA NA 3 (10.0%) NA        | NA NA NA 1 (3.3%) NA NA 8 (26.7%) |
| Zeng 2010 [20] | 22/26           | 2 (9.1%) NA NA NA          | 9 (34.6%) NA NA NA            | 0 (0%) NA NA NA 4 (15.4%) NA NA NA |
| Zhang 2010 [21] | 60/60           | 6 (10.0%) NA NA NA         | 18 (30.0%) NA NA NA           | 5 (18.3%) NA NA 1 (1.7%) 18 (30.0%) NA NA 11 (18.3%) |
| Yao 2011 [23]  | 28/30           | 1 (3.6%) 0 (0%) NA NA     | 5 (16.7%) 4 (13.3%) NA NA    | NA NA NA NA NA NA NA NA NA |
| Han 2011 [5]   | 136/94          | 13 (9.6%) NA 0 (0%) NA     | 28 (29.8%) NA 7 (8.0%) NA    | 0 (0%) NA 0 (0%) NA 9 (9.6%) NA 7 (8.0%) NA |

HBsAg: hepatitis B surface antigen; NA: not available.
immunoprophylaxis. However, approximately 10–15% of newborns from HBV carrier mothers suffer from HBV infection because of intrauterine transmission. MTCT, which includes intrauterine transmission, perinatal transmission and transmission during lactation, is an important reason for failure of immune prophylaxis. It has been demonstrated that active immunisation (HBVac) combined with passive immunisation (HBIG) can effectively prevent perinatal transmission and transmission during lactation. Nonetheless, the incidence of intrauterine HBV infection remains as high as 43% when maternal serum HBV DNA exceeds 10^8 copies/ml, even with prompt administration of active and passive vaccination. del Canho et al. also reported that intrauterine infection occurs only when maternal serum HBV DNA levels are high (> 150 pg/ml or 3.16 × 10^7 copies/ml). Intrauterine HBV transmission occurs primarily during the third trimester and is presumed to cause a minority of the infections not prevented by prompt immunisation. Probable reasons for transmission are thought to be the breach of the placental barrier caused by HBV and polymorphisms in some cytokine genes (such as those encoding for interferon-γ and tumour necrosis factor-α) [33].

In general, it is not recommended to initiate antiviral therapy with nucleoside analogues in HBV-infected persons who are immune tolerant. However, they have the same risk of intrauterine infection as CHB patients. Lamivudine, the first nucleoside analogue inhibitor to be approved for the treatment of CHB, has long been used for both HIV and HBV infection during pregnancy and has displayed reliable prevention effects. Although lamivudine is classified as FDA pregnancy risk category

**Figure 5** Forest plots of telbivudine vs. control on newborn HBV DNA seropositivity.

**Figure 6** Forest plots of telbivudine vs. control on infant HBV DNA seropositivity at age 6–12 months. A. Pooled effect from the combination of RCTs and NRCTs. B. Pooled effect from NRCTs.
C, the European Association for the study of the Liver also confirmed its safety during late pregnancy in 2009 [35]. However, it was also reported that reducing maternal HBV DNA levels even to undetectable status by lamivudine in late pregnancy could not guarantee prevention of intrauterine HBV infection in the newborns [36]. Telbivudine was approved by the FDA in 2006 and the State Food and Drug Administration in 2007 for the treatment of patients with CHB, and has demonstrated faster and better efficacy than lamivudine in patients with HBeAg-positive and HBeAg-negative CHB disease.

A few studies have evaluated the efficacy of telbivudine application in preventing intrauterine HBV infection during late pregnancy. Therefore we conducted this meta-analysis to arrive at an evidence-based conclusion. In this meta-analysis, the treatment group consisted of 306 mothers who received 600 mg/d telbivudine from the second or third trimester of pregnancy until delivery or 1 month after delivery. The control group consisted

| Study or Subgroup | Telbivudine Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI Year |
|-------------------|------------------|----|-------|--------------|----|-------|--------|--------------------------------------|
| Zhang 2009        | 7.38             | 0.81| 31    | 7.46         | 0.45| 30    | 14.9% | -0.08 [-0.41, 0.25] 2009              |
| Zhang 2010        | 7.66             | 0.82| 22    | 7.13         | 1.29| 26    | 4.4%  | 0.53 [0.07, 1.13] 2010                 |
| Zhang 2010        | 6.82             | 5.95| 60    | 6.86         | 6.1 | 60    | 0.3%  | -0.04 [-2.20, 2.12] 2010               |
| Yeo 2011          | 7.5              | 0.6 | 28    | 7.5          | 0.7 | 30    | 14.2% | 0.00 [-0.33, 0.33] 2011                |
| Han 2011          | 8.1              | 0.56| 135   | 7.98         | 0.61| 94    | 66.1% | 0.12 [-0.04, 0.28] 2011                |

Total (95% CI) 276 240 100.0% 0.09 [-0.04, 0.22]

Heterogeneity: Chi² = 3.52, df = 4 (P = 0.48); I² = 0%
Test for overall effect: Z = 1.41 (P = 0.16)

| Study or Subgroup | Telbivudine Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI Year |
|-------------------|------------------|----|-------|--------------|----|-------|--------|--------------------------------------|
| Zhang 2010        | 7.66             | 0.82| 22    | 7.13         | 1.29| 26    | 5.2%  | 0.53 [-0.07, 1.13] 2010                 |
| Zhang 2010        | 6.82             | 5.95| 60    | 6.86         | 6.1 | 60    | 0.4%  | -0.04 [-2.20, 2.12] 2010               |
| Yeo 2011          | 7.5              | 0.6 | 28    | 7.5          | 0.7 | 30    | 16.7% | 0.00 [-0.33, 0.33] 2011                |
| Han 2011          | 8.1              | 0.56| 135   | 7.98         | 0.61| 94    | 77.7% | 0.12 [-0.04, 0.28] 2011                |

Total (95% CI) 245 210 100.0% 0.12 [-0.02, 0.26]

Heterogeneity: Chi² = 2.29, df = 3 (P = 0.51); I² = 0%
Test for overall effect: Z = 1.72 (P = 0.08)

Figure 7 Forest plots of telbivudine vs. control on maternal blood HBV DNA levels before treatment. A. Pooled effect from the combination of RCTs and NRCTs. B. Pooled effect from NRCTs.

Figure 8 Forest plots of telbivudine vs. control on maternal blood HBV DNA levels prior to delivery. A. Pooled effect from the combination of RCTs and NRCTs. B. Pooled effect from NRCTs.
of 270 mothers who did not receive any antiviral drug. All newborns received HBIG and HBVac after birth. The pooled results clearly showed that the seropositivity rate for HBsAg or HBV DNA was significantly lower in the telbivudine group, both at birth and at 6–12 months follow-up. Meanwhile, maternal HBV DNA levels prior to delivery were significantly lower in the telbivudine group. We further conducted meta-analysis based on study type (RCT or NRCT) to minimise any potential heterogeneity and found that the type of study design did not affect the conclusion. However, we should pay more attention to the evidence grades of these included trials. Because published studies were limited, only six trials were included in the meta-analysis. Two trials contained randomised controls, but the details of the randomisation sequence were not provided. The other four trials included non-randomised controls. In the Han [5], Zeng [20] and Zhang, 2010 [21] studies, the mothers self-selected themselves into one arm or the other. When some demographic features were presented, more of the control group had abnormal ALT levels [5]. In Yao’s study [23], the mothers were divided into different groups according to baseline ALT levels. Thus, more high-quality, well-designed and randomised controlled multi-centre trails are necessary to verify the results in the future.

As an orally bioavailable L-nucleoside analogue with potent activity against HBV, telbivudine has shown no effects on human nucleotides and DNA synthesis [37]. Toxicology research has also demonstrated that telbivudine has no significant organ toxicity, carcinogenicity, genotoxicity, mitochondrial toxicity in vitro, teratogenicity, or embryo-foetal toxicity [13,38]. In the phase III GLOBE trial, most adverse events reported were classified as mild or moderate in severity and were not attributed to telbivudine, and elevations in serum CK were more common in the telbivudine group. Based on its characteristics, telbivudine is listed by the FDA as a pregnancy category B drug. The treatment guidelines of the Asian Pacific Association for the Study of the Liver also designated telbivudine as a replacement antiviral therapy during pregnancy in 2008 [39]. In our meta-analysis we analysed elevations in serum CK, elevated ALT levels after drug withdrawal and other adverse events. Since the reported studies only evaluated the short-term effects of telbivudine and only a few studies reported adverse events, the long-term safety of telbivudine in infants still need to be assessed in the future. In addition, we found that the number of infected infants at age 6–12 months was less than the number of infected newborns. The probable reason for this decline is that maternal blood containing HBsAg and HBV DNA was introduced into the bodies of the newborns through the umbilical cord during delivery, which were later neutralised by anti-HBs of HBIG [40].

To our knowledge, this is the first systematic meta-analysis of this topic. We are convinced that our search strategy was comprehensive and exhaustive. We comply with the standardized guidelines on the reporting of systematic reviews according to the PRISMA statement and the PRISMA checklist (see Additional file 1). Two investigators (Min Deng and Xin Zhou) independently extracted data and entered them in a customised form. Disagreements were resolved by consensus when necessary. However, the following limitations of our meta-analysis should be considered. First, we searched for studies published only in English or Chinese. Second, due to limited published studies, we expanded the search to include NRCTs. Third, only a few studies were included and they had small sample sizes. For these reasons, we could not perform a deep analysis. Besides, all included studies were performed in mainland China. Therefore, more clinical studies performed in different populations and other regions are necessary to access the generalisability of the results.

Conclusions

Our meta-analysis provides preliminary evidence that telbivudine application in late pregnancy is effective in the interruption of intrauterine HBV infection, with no
significant adverse effects or complications. More high quality, well-designed, double-blinded, randomised controlled and large size clinical trials are needed for further investigation and more convincing results in the future.

Additional file

Additional file 1: PRISMA 2009 Checklist.

Abbreviations
HBV: Hepatitis B virus; RR: Relative risk; HBsAg: Hepatitis B surface antigen; MD: Mean difference; RCTs: Randomized controlled trials; NRCTs: Non-randomized controlled trials; HBVAC: Hepatitis B vaccine; HBIG: hepatitis B immunoglobulin; CK: Creatine kinase; CHB: Chronic Hepatitis B; MCTT: Mother-to-child transmission; HBeAg: Hepatitis B e antigen; FDA: the Food and Drug Administration; ALT: Aminotransferase; CI: Confidence interval.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
RB conceived the study and revised the manuscript critically for important intellectual content. DM and ZX made substantial contributions to its design, acquisition, analysis and interpretation of data. All authors read and approved the final manuscript.

Author details
1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China. 2Key Laboratory of Combined Immunological Patterns of Infectious Diseases, Taizhou Hospital Affiliated to Wenzhou Medical College, Linhai, Zhejiang 317000, China.

Received: 6 April 2012 Accepted: 28 August 2012 Published: 4 September 2012

References
1. Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ: Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas, Epidemiol Infect 1996, 117:313–325.
2. Tran TT: Management of hepatitis B in pregnancy: weighing the options. Clev Clin J Med 2009, 76(Suppl 3):S52–S59.
3. Jonas MM: Hepatitis B and pregnancy: an underestimated issue. Uiver Int 2009, 29(Suppl 1):133–139.
4. Grosheide PM, del Canho R, Heijink RA, Nijsten AS, Zwijsenberg J, Bänffer JR, Wladimiroff JW, Botman MJ, Mazel JA, de Gast GC: Passive-active immunization in infants of hepatitis B antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization. Am J Dis Child 1993, 147:1316–1320.
5. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX: A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011, 55:1215–1221.
6. Xu DZ, Yan YP, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, et al: Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16:94–103.
7. Li XM, Shi MF, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ: Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004, 10:3215–3217.
8. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, et al: Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16:94–103.
9. Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y: Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004, 10:910–912.
10. Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, Li AM, Shi MF, Zou L: Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003, 9:1501–1503.
11. van Zonneveld M, van Nuenen AB, Nieters HG, de Man RA, Schalm SW, Janssen HL: Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003, 10:294–297.
12. Li W, Jiang R, Wei Z, Li Y: Clinical effect and safety of lamivudine in interruption of chronic HBV maternal to infant transmission. Chin Hepatol 2008, 11:106–107.
13. Hou J, Yin YK, Xu O, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, et al: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology 2008, 47:447–454.
14. Lai CL, Gane E, Liaw YF, Hsu CW, Chongswat W, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, et al: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576–2588.
15. Yang Y, Deng L, Li X, Xu Z, Jiang D, Chen D, Yu Y, Tang Z, Wang X, Zhao S, et al: Analysis of prognosis-associated factors in fulminant viral liver disease during pregnancy in China. Int J Gynaecol Obstet 2011, 114:242–245.
16. Shi Z, Li M, Li Y: Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. Int J Infect Dis 2010, 14:e622–e634.
17. Didier AR, Moore RA, Carroll D, Jenkinsin C, Reynolds DJ, Gavaghan DJ, Hu M: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1–12.
18. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177–188.
19. Zhang J, Wang L: Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2009, 17:561–563.
20. Zeng Y, Zhang S, Lou G, Chen J, Shi J, Liu S, Huang J: Clinical study of telbivudine to interrupt intrauterine transmission of Hepatitis B virus. Chin J Clin Pharmacol Ther 2010, 15:443–445.
21. Zhang Y, Hu Y: Efficacy and safety of telbivudine in preventing mother-to-infant HBV transmission. Adverse Drug Reactions Journal 2010, 12:157–159.
22. Zhao D, Liao X, Peng G, Liu J, Lin C: Effects of Telbivudine joint hepatitis B vaccine and hepatitis B immunoglobulin to interrupt mother-to-child transmission: a randomized controlled trial of 60 cases. Chin J Mod Drug Appl 2010, 43:38–38.
23. Yao Z, Chen M, Liao W, Zhang Y, Wu Y, Li L, Feng J, Lin M, Chen C, Zheng D, Zeng J: The efficacy and safety of telbivudine in blocking intrauterine hepatitis B virus transmission. J Clin Hepatol 2011, 14:259–261.
24. Jiang Q, Liang W, Zhang S, Zeng Y, Meng Y, Zhang Y, Lou G: New research for efficacy of telbivudine blocking HBV transmission from mother to child. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010, 24:286–288.
25. Zeng Y, Zhang S, Lou G, Chen J, Shi J, Liu S, Huang J: 23 cases of telbivudine joint hepatitis B immunoglobulin to interrupt HBV mother-to-child transmission. J Pract Med 2010, 26:3012–3014.
26. Huang CF, Dai CY, Chuang WL, Ho CK, Wu TC, Hou NJ, Wang CL, Hsieh MY, Huang JF, Lin ZY, et al: HBV infection in indigenous children, 20 years after immunization in Taiwan: a community-based study. Prev Med 2009, 48:397–400.
27. Wang Z, Zhang J, Yang H, Li X, Wen S, Gao Y, Sun J, Hou J: Quantitative analysis of HBV DNA level and HBeAg titre in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003, 71:360–362.
28. Lee C, Gong Y, Brok J, Boxall EH, Gluud C: Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2000, 323:328–336.
29. Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, Sun W, Zhao X, Yang X, Zhang L, et al: Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med 2011, 165:837–846.
30. Choe B, Lee J, Jang Y, Jang C, Oh K, Kwon S, Hyun M, Ko C, Lee K, Lee W: Long-term therapeutic efficacy of lamivudine compared with
interferon-α in children with chronic hepatitis B: The younger the better.  
*J Pediatr Gastroenterol Nutr* 2007, 44:92–98.

31. del Canho R, Grosheide PM, Mazel JA, Heijtink RA, Hop WC, Gerards LJ, de Gast GC, Fetter WP, Zwijsenberg J, Schalm SW: Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982–1992: protective efficacy and long-term immunogenicity. *Vaccine* 1997, 15:1624–1630.

32. Yan Y, Xu D, Wang W: The role of placenta in hepatitis B virus intrauterine transmission. Zhonghua Fu Chan Ke Za Zhi 1999, 34:392–395.

33. Yu H, Zhu Q-R, Gu S-Q, Fei L-E: Relationship between IFN-gamma gene polymorphism and susceptibility to intrauterine HBV infection. *World journal of gastroenterology: WJG* 2006, 12:2928–2931.

34. Shi Z, Yang Y, Ma L, Li X, Schreiber A: Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. *Obstet Gynecol* 2010, 116:147–159.

35. Papatheodoridis GV, Manolakopoulos S: EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. *J Hepatol* 2009, 51:226–227.

36. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK: Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. *Lancet* 2002, 359:1488–1489.

37. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE: Clinical pharmacokinetics of lamivudine. *Clin Pharmacokinet* 1999, 36:41–66.

38. Dienstag J, Easley C, Kirkpatrick P: Telbivudine. *Nature reviews Drug discovery* 2007, 6:267–268.

39. Liaw Y-F, Leung N, Kao J-H, Piratvisuth T, Gane E, Han K-H, Lau GK, Locarnini S: Chronic Hepatitis B GWPotA-PAPfSotL: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. *Hepatology international* 2008, 2:263–283.

40. Han Z-H, Zhong L-H, Wang J, Zhao Q-L, Sun Y-G, Li L-W, Cao L-H, Hao X-C, Zhuang H: The impact of antepartum injection of hepatitis B immunoglobulin on maternal serum HBV DNA and anti-HBs in the newborns. Zhonghua nei ke za zhi [Chinese journal of internal medicine] 2007, 46:376–378.

doi:10.1186/1743-422X-9-185

Cite this article as: Deng et al.: The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. *Virology Journal* 2012 9:185.